Aim To test the potential benefit of extending cognitive-behavioral therapy (CBT) relative to not extending CBT on longterm abstinence from smoking. Design Two-group parallel randomized controlled trial. Patients were randomized to receive non-extended CBT (n = 111) or extended CBT (n = 112) following a 26-week open-label treatment.
INTRODUCTION
Smoking cessation therapy is provided typically for 8-12 weeks. This paper presents results of an investigation on the efficacy of smoking cessation therapy when extended beyond the conventional 8-12-week treatment regimen. Adult smokers received 26 weeks of open-label treatment with cognitive behavior therapy (CBT) and pharmacotherapy (nicotine patch, bupropion SR, varenicline), followed by 26 weeks of CBT or brief telephone contact.
This investigation is of interest for several reasons. First, most cigarette smokers relapse following treatment [1] . A recent systematic review and meta-analysis reported that average abstinence rates (6 months or more) were 17, 19, 27 and 31% for nicotine replacement therapy (NRT), bupropion, varenicline and combination NRT, respectively [2, 3] . Therefore, treatments are needed that enable more sustained effects on abstinence.
Secondy, research indicates drug addiction is a chronic, relapsing brain disorder requiring extended therapy and follow-up [4, 5] . However, few studies of extended smoking cessation treatment have been conducted. NRT [6] [7] [8] [9] , bupropion [10] [11] [12] [13] [14] , nortriptyline [15] and varenicline [16] have been examined with extended treatment protocols [16] . Point-prevalence abstinence rates at 52 weeks for extended treatment ranged from 14 to 26% for NRT [8, 9] , 28-55% for bupropion [12] [13] [14] , 50% for nortriptyline [15] and 43% for varenicline [16] .
We have reported previously results from two trials of adult smokers examining extended treatment with openlabel consisting of combination bupropion SR + NRT + CBT for 11-12 weeks [12, 13] . In the first trial [12] , overall point-prevalence abstinence rates in the extended group exceeded 40% at 24-week follow-up and 30% at 52-week follow-up. In the second trial [13] , point-prevalence abstinence rates were higher for extended CBT compared to telephone support at 20-week follow-up (extended CBT: 45% versus telephone: 29%). Hall and colleagues examined an extended therapy protocol with bupropion SR and CBT for 12 weeks, then randomized to either 40 weeks of extended CBT combined with bupropion SR, 40 weeks of bupropion SR without CBT, 40 weeks of placebo or no further treatment [14] . The extended CBT plus bupropion SR group had superior point-prevalence abstinence rates than all other treatment groups out to 104 weeks (47%). However, another trial by these investigators randomized smokers to 40 weeks of CBT with or without extended NRT, 40 weeks of NRT alone, 40 weeks of CBT or no further treatment [7] . The extended CBT without NRT produced superior abstinence rates out to 104 weeks (55%). Moreover, meta-analyses reported in a recent Cochrane review suggested that extending the duration of combination CBT and pharmacotherapy can improve long-term (6-month or longer) abstinence rates [17] .
Thirdly, there is evidence that treatment efficacy could be enhanced by combining more intensive interventions with self-help approaches, telephone counseling and methods for the rapid identification and treatment of smoking lapses [7] [8] [9] [12] [13] [14] [17] [18] [19] . Each of these components was incorporated into the multi-factor treatment approach tested in this randomized clinical trial (RCT).
Fourthly, we used an adaptive treatment approach to adjust pharmacotherapy based on self-reports of factors known to predict relapse; namely, craving and depressive symptoms [20, 21] . Adaptive treatment protocols have increased smoking cessation rates beyond conventional approaches for smokers not responding to pre-cessation NRT [20, 21] and when negative mood changes developed after initial treatment [22] . As such, the present study used smokers' self-reports of craving and depressive symptoms to guide the provision of pharmacotherapy.
The primary purpose of this trial was to determine whether patients would benefit from extended duration of CBT. Patients were randomized to receive either nonextended CBT or extended CBT following the adaptive treatment phase. The primary study end-point was 7-day point-prevalence 104 weeks, at which point the only factor that differed systematically between groups was duration of CBT.
Primary hypothesis
Extending CBT from 26 to 48 weeks should produce higher expired-air carbon monoxide (CO)-confirmed 7-day point-prevalence and prolonged abstinence rates at 52-and 104-week follow-ups in treatment-seeking smokers treated with open-label combination bupropion SR plus NRT.
METHOD

Study design
A total of 223 cigarette smokers (18-65 years of age; smoking ≥10 cigarettes per day or 3.5 packs per week) were randomized between 1 June 2010 and 22 January 2013. The final sample size available for analyses was 219, because two participants died (causes unrelated to treatment) and two were withdrawn (tachycardia, threatening behavior). With more than 100 participants per condition, the trial had 80% power at a two-tailed alpha of 0.05 to detect a difference in abstinence rates of at least 15% over a range of success probabilities (10%, 25% 104-week abstinence). The Stanford University Panel for the Protection of Human Subjects in Medical Research approved the study protocol.
The trial included open-label and extended treatment phases. Follow-ups were conducted at 52 and 104 weeks. The trial was funded by the National Institute on Drug Abuse and registered with clinicaltrials.gov.
Participants were randomized to extended or nonextended treatment at week 1 after a successful 24-hour quit. The randomization was blinded and revealed to participant and treatment staff only after the week 24 visit. Randomization assignments to extended treatment were generated following the adaptive treatment phase based on intention-to-treat [23] . Males and females were randomized separately, using an algorithm that employed a weighted randomization scheme [13] . Specifically, if there were equal numbers of males already randomized to the two conditions, the probability that the next male would be randomized to group 1 was 50%. If more males were already randomized to group 1, there was only a 33.33% chance that the next participant would be randomized to group 1. If there were fewer males already randomized to group 1, then there was a 66.67% probability that the next participant would be randomized to group 1. The same method was used for females. Study staff and participants were blinded to randomized treatment assignment until the end of the open-label phase. Figure 1 illustrates the study design.
Open-label treatment (weeks 1-26)
Individualized, therapist-directed CBT was provided to all participants to week 26. Nicotine patch (21 mg) and bupropion SR (300 mg) was the standard treatment provided to all participants to week 10, with the exception of certain conditions [i.e. presentation of elevated systolic (≥ 170) or diastolic (≥ 110) blood pressure and/or heart rate ≥ 120, medication interaction or medical contraindication] as determined by the study physician, in which case participants were administered NRT only. At week 10, those who were abstinent [self-report + expired air carbon monoxide < 10 parts per million (p.p.m.)] and who reported low cravings and depressive symptoms were withdrawn from NRT and bupropion SR. Those who were abstinent but who reported high cravings or depressive symptoms were continued on NRT and a lower-dose bupropion SR to week 26. At week 10, participants who continued to smoke set a new quit date and were switched to treatment with varenicline alone to week 26. Finally, participants who were withdrawn from NRT and bupropion SR but subsequently experienced increases in cravings or depression symptoms during open-label treatment were re-started on NRT and bupropion SR to week 26.
Extended treatment (weeks 27-52)
Half the sample received an additional 24 weeks of CBT (extended CBT; E-CBT) that included both therapistdirected, self-directed components, continued slip detection and rapid treatment response. Remaining participants (non-extended CBT) received brief telephone calls to check abstinence status on a monthly basis from weeks 28 to 52; no therapy was provided.
STUDY POPULATION
Participants were recruited via advertisements on the radio, television, posted flyers, newspapers, ResearchMatch.org, referrals from local quit lines, advertisements on public transportation and information tables at local companies. Interested smokers completed a telephone screen and, if eligible, were scheduled for an initial clinic visit where they signed consent forms, completed a structured clinical interview to detect major depression, suicide attempts and drug abuse; the modified Fagerström Tolerance Questionnaire (mFTQ) was also administered. The study psychiatrist determined eligibility for those with suicidal ideation. Basic physical examinations were paid for by the study and reviewed by the study physician to determine eligibility.
Eligible participants returned to complete questionnaires, provide a refundable $50 deposit, set a quit date for approximately 7 days from the baseline visit and receive study medications. The deposit was returned contingent upon completion of follow-ups conducted at 26, 52 and 104 weeks. Participants received a $25 gift card upon completion of the 104-week follow-up. Payment was not contingent upon quitting smoking successfully. Approval from the study medical director was required to be enrolled into the study. Expired-air CO was measured at all visits using the Bedfont Smokerlyzer (Bedfont Scientific Ltd, Maidstone, UK; www.bedfont.com).
SCREENING
Individuals were excluded for pregnancy, current lactation, epilepsy, bipolar disorder, schizophrenia or reporting current depression or substance abuse, history of heart problems in the previous 6 months, head trauma leading to unconsciousness in the past year, history of severe head injury resulting in brain surgery or specific neurological problems, current use of bupropion or NRT or medication contraindicated for use with bupropion or NRT.
TREATMENTS
Health educator training
Counseling was conducted by health educators, who were trained by a PhD-level clinical psychologist and supervised by a project manager, who received tobacco use treatment certification training. Treatment fidelity was evaluated by the clinical psychologist, psychiatrist and project manager who met with health educators after patient visits [12, 13, 18, 24, 25] . 
Open-label: CBT
Intensive, manual-based, therapist-directed CBT with a thorough skills mastery experience was provided to participants during the open-label phase of treatment. The therapy equipped smokers with the requisite selfregulatory skills to cope with the non-pharmacological factors that maintain cigarette smoking and precipitate relapse [25] . Skills mastery is achieved most thoroughly through interventions that employ modeling, guided rehearsal and self-directed application of regulatory skills [26] .
At each clinic session, staff met with participants individually for approximately 30 minutes to develop cognitive and behavioral skills to resist urges to smoke. Staff used self-efficacy questionnaires to assess participants' confidence in their abilities to resist urges to smoke in specific situations and behavioral worksheets to help participants articulate treatment plans to be used in managing their behavior in these situations without smoking. All treatment sessions were led by trained health educators.
During maintenance treatment, intensive training was phased out and participants were shifted to self-directed intervention designed to bolster their confidence in using cognitive behavioral skills with minimal direct therapist aid or contact.
Open-label: pharmacotherapy
Participants received nicotine patch (21 mg) and bupropion SR (300 mg) to week 10. At week 11, they were switched to one of three groups based on smoking status, craving and depressive symptoms: (1) no medicationstudy medications were discontinued if the participant reported not smoking in the past week, expired CO level < 10 p.p.m. and craving and depressive symptoms did not increase from baseline; (2) bupropion (150 mg) + NRT (21 mg)-participants in this group were continued on bupropion SR + NRT if self-reported not smoking in the past week, expired CO level < 10 p.p.m., but reported increased craving or depressive symptoms from baseline; and (3) varenicline -participants were switched to varenicline and discontinued bupropion and NRT if expired CO level > 10 p.p.m. or participant self-reported relapse. A new quit date was set and varenicline was titrated up to 2 mg/day during the course of a week.
Participants in the no medication condition who reported a relapse, increased craving or depressive symptoms during weeks 12-22 were reinstated on bupropion SR (150 mg) + NRT (21 mg). Those who reported increased craving or depressive symptoms at week 24 were reinstated on NRT (21 mg) to week 26.
Extended CBT (weeks 27-52)
Participants randomized to receive extended CBT continued to work with staff individually on the development and use of cognitive and behavioral cessation and relapse prevention skills. Treatment sessions were conducted at the San Jose clinic site in weeks 28, 30, 
Control: check-in telephone calls
Participants randomized to the non-extended condition received a monthly phone call from the health educator during weeks 28-48 to assess smoking status.
MEASURES
Primary study end-point
The primary study end-point was expired-air COconfirmed 7-day point-prevalence (PP) abstinence evaluated at 52 and 104 weeks. This end-point measure is defined as a report of non-smoking (not even a puff) for 7 consecutive days prior to contact plus an expired-air CO level < 10 p.p.m. At all clinic and phone contacts smoking status was determined via the query: 'Have you smoked a cigarette, even a puff, in the past week?'. Expired-air CO was measured at all clinic visits with the Bedfont EC50 Smokerlyzer (Bedfont Scientific Ltd).
Secondary study end-point
The secondary end-point was prolonged abstinence (PA), defined as self-reported non-smoking following a 2-week grace period. Treatment failure was operationalized as smoking for 7 consecutive days or ≥ 1 day in each of 2 consecutive weeks. Self-reported smoking status was assessed by the question: 'Since your first quit date of the study, have you smoked, even a puff, 7 days in a row?'.
Individuals who did not provide biochemical verification were classified as smokers, with the exception of individuals who moved out of the area during the posttreatment follow-up period.
Measures of nicotine dependence
Craving
Craving was measured by taking the average response to the questions: 'Have you felt cravings for a cigarette?' and 'Have you felt strong urges to smoke?'. Participants rated how upsetting their cravings had been in the past 24 hours on a scale from 'not upsetting' to 'extremely upsetting' [27] . Craving was measured to week 26.
The Center for Epidemiological Studies Depression Scale (CED): the CES-D, a 20-item self-report scale designed to measure depressive symptomology, was administered to week 26 [28] .
The five-item questionnaire, the modified Fagerström Tolerance Questionnaire (mFTQ), was used to quantify level of nicotine dependence. Higher scores indicated greater dependence [29] . This measure was taken at baseline.
Self-efficacy
Self-efficacy was measured using a 17-item instrument adapted from Baer, Holt & Lichtenstein [26] . Participants rated their level of confidence in resisting the urge to smoke if they were to quit at that moment. Ratings were made on a scale from 0 to 100%. This measure was taken at baseline.
Physiological measures
Heart rate and blood pressure were measured twice at each clinic visit during the open-label phase with an automated blood pressure device (DINAMAP XL 9300; Johnson & Johnson Medical, Inc., New Brunswick, NJ, USA). All blood pressure levels were reported to participants and those with elevated levels were advised to see their physicians. Height and weight were also recorded.
Adverse events
Adverse events related to use of study medication was assessed at each visit or by phone during open-label treatment. The study medical director or psychologist reviewed reports of serious adverse events; medication was adjusted accordingly.
Medication compliance
At each assessment during open-label treatment, participants were asked if they were 'wearing a patch now', if they had 'taken 
Analyses
Statistical analyses were deemed statistically significant at α = 0.05 for all analyses.
Adjusting covariates
Multicollinearity diagnostics were performed on potentially confounding prognostic characteristics assessed at baseline. Predictors were standardized and entered into a simultaneous multiple linear regression to obtain variance inflation factor (VIF) statistics and eigenvalues. Predictors with large proportions of variation for small eigenvalues tend to be correlated highly and were considered for exclusion or recombination. Predictors identified as independent were used as adjusting covariates in outcome analyses. Baseline variables identified a priori as having prognostic strength were included whether the imbalances between randomized groups were statistically significant.
Abstinence outcomes
Analyses on abstinence were compared as randomized (intention-to-treat: ITT). Potential effects of E-CBT versus non-extended CBT were tested using the odds ratio (OR) with 95% confidence interval (CI). Adjusting covariate logistic regressions tested the effect of treatment for each follow-up time-point.
Adverse event incidences were compared using χ 2 tests.
RESULTS
Study sample
Study staff contacted 1241 individuals interested in participating [see Fig. 2 for Consolidated Standards Of Reporting Trials (CONSORT) diagram]. After learning more about the study 766 remained interested; of these, 223 were randomized. A total of 219 participants were included in the intent-to-treat analysis (E-CBT: n = 108; non-extended CBT: n = 111) because two participants died (causes unrelated to treatment) and two were withdrawn (tachycardia, threatening behavior). The ethnic/racial distribution was 78% white (n = 171), 3% African American (n = 6), 8% Asian (n = 18), 1% American Indian/Alaska native (n = 3), 4% more than one race (n = 10) and 5% unknown/other (n = 8). There was no evidence of a significant difference in follow-up rates between treatment groups, P > 0.05. 
Adjusting covariates
Abstinence during open-label treatment
There were no significant group differences in PP abstinence at 10 weeks (OR = 0.98, 95% CI = 0.56, 1.72). Table 2 shows the 26-week PP abstinence rates for participants allocated to (1) varenicline, (2) bupropion SR + NRT, (3) no medication or (4) discontinuation of medication and then reinstatement of bupropion and NRT; the treatment × drug group interaction was not statistically significant, χ
2
(1) = 3.69, P = 0.30. Table 2 shows no benefit of extending CBT on any primary or secondary outcome measure. PP-abstinence rates at the 52-week follow-up were comparable across non-extended CBT (40%) and E-CBT (39%) groups (OR = 0.99, 95% CI = 0.55, 1.78). Similar results were obtained for PP-abstinence rates at the 104-week follow-up across CBT (39%) and E-CBT (33%) groups (OR = 0.79, 95% CI = 0.44, 1.40). Unadjusted analyses yielded similar results (Table 3 ).
Abstinence outcomes
Re-classification
Of self-reported non-smokers, 100, 81, 84 and 84% provided biochemical confirmation of abstinence at 10, 26, 52 and 104 weeks, respectively. Those who reported abstinence but failed to provide breath samples for carbon monoxide verification were reclassified as smokers, with the following exceptions. The number of participants who had moved out of the area but self-reported abstinence without CO verification were: week 52, non-extended CBT, n = 4, E-CBT, n = 5; week 104, non-extended CBT, n = 3, E-CBT, n = 8.
Medication compliance
Weeks 1-10
Eighty-nine per cent of participants responded 'yes' when asked if they had taken their bupropion SR pill at one or more visits and 98% reported using their nicotine patch at one or more visits. The mean number of visits (of 10) when participants reported taking bupropion was 5.8 [standard deviation (SD): 3.6] and NRT was 6.1 (2.9) in the non-extended group and 6.1 (3.6) and 6.2 [3] in the E-CBT group, respectively.
Weeks 11-26
Among individuals continued on initial treatment, 69% of participants reported taking their bupropion SR pill at one or more visits and 79% reported wearing the patch at one or more treatment session. Regarding participants switched to varenicline, 82% reported taking the medication at one or more treatment sessions. The mean number of visits (of nine) when participants reported taking bupropion was 1.6 (2.4), NRT was 1.5 (2.3) and varenicline was 3.3 (2.6) in the non-extended group, and 2.4 (2.9), 2.3 (2.8) and 2.9 (2.5) in the E-CBT group, respectively.
CBT session attendance
Weeks 1-26
The non-extended CBT group attended an average of 12.5 sessions while the E-CBT group attended an average of 12.4 sessions (5.3) of the 19 CBT sessions.
Weeks 27-48
The E-CBT group attended an average of 2.8 (3.1) of the nine sessions.
Adverse events
One individual was removed from the trial after an episode of tachycardia. The most frequent adverse events in weeks 1-10 were anxiety, dry mouth and insomnia, all which were more common in males. Adverse events were less common in weeks 11-26. There were no statistically significant differences in adverse events between treatment groups (Ps > 0.05).
DISCUSSION
The present study tested whether extending CBT from 26 to 48 weeks would enhance long-term abstinence rates. Although we did not find direct support for this hypothesis, the average long-term quit rates observed in the present study were higher than those observed in trials of brief behavioral interventions lacking maintenance treatment and were comparable to studies of maintenance treatment extended up to 26 weeks [30] . Based on results from a meta-analysis by the Cochrane Collaboration, estimates of abstinence rates following pharmacological treatment combined with behavioral treatment ranged from 17 to 31% for different combinations of pharmacotherapies (NRT, bupropion SR, combination NRT, varenicline) at 26 weeks; our treatment produced abstinence rates near 40% and for a longer duration [2] .
One explanation for a lack of effect of extended-CBT treatment could be that regular, intensive, in-person CBT beyond approximately 6 months produced treatment fatigue and diminished returns of ongoing treatment. The finding that the E-CBT group attended 65% of sessions during weeks 1-26 compared to 31% in weeks 27-48 is consistent with this hypothesis. This account is also consistent with extant trials reporting reduced attendance with extended CBT [14] and declines in efficacy resulting from the combination of multiple behavioral treatments beyond brief interventions [31] .
Participants in the extended CBT group may have derived additional benefited from extended pharmacotherapy treatment. Indeed, Hall and colleagues found that smokers who received 12 weeks of combined bupropion SR + NRT followed by 40 weeks of extended CBT and bupropion SR had somewhat higher 104-week abstinence rates than participants in our study. However, other trials have reported that when active drug was administered in combination with CBT, effects were lost upon medication termination. Hall and colleagues [7] have also reported that extending NRT did not add to the efficacy of CBT. Collectively, these results suggest pharmacotherapies might have a time-sensitive threshold of effectiveness. However, the aforementioned studies used standard pharmacotherapy protocols, and thus the potentially positive effects of extending adaptive pharmacotherapy before being switched to nonpharmacological treatments are unknown.
Hall and colleagues found that although patients assigned to extended CBT + active bupropion SR or extended CBT + placebo produced better long-term abstinence rates than standard treatments, they did not differ from one another [14] . The authors suggested periodic check-ins might be as effective as an active drug and counseling. Indeed, such an explanation could account for why we did not detect an effect of extending CBT; check-up calls in the control group to week 48 may have been sufficient to maintain abstinence. It is surprising that abstinence rates in the present RCT were comparable to those obtained with more aggressive extended treatments.
It is difficult to comment upon how this study might inform treatment of lighter smokers because (1) we excluded lighter smokers from the study and (2) there was no relationship between smoking and relapse rates, Ps > 0.05. None the less, the aggressive treatment plan used in the present study may not be suited for those with lower smoking rates.
Future clinical trials should bear in mind the importance of testing for predictors of treatment failure. For instance, combination treatment studies should attend more closely to the relationship between medication noncompliance versus CBT non-attendance, how this differs by treatment phase and for which subgroups.
In summary, our study suggests that CBT treatment beyond 26 weeks does not increase long-term abstinence rates. This could be explained by reduced compliance with extended CBT owing to treatment fatigue. Alternatively, there could be some time threshold wherein additional treatment is not efficacious.
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